Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (5y) (2016 - 2026)
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.46 Bn | 34.45 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.77% |
| Dec 31, 2025 | 187.20% |
| Sep 30, 2025 | 25.05% |
| Jun 30, 2025 | 43.98% |
| Mar 31, 2024 | -9.80% |
| Dec 31, 2023 | -36.88% |
| Sep 30, 2023 | 15.06% |
| Jun 30, 2023 | 47.30% |
| Dec 31, 2022 | 15.07% |
| Sep 30, 2022 | 52.20% |
| Jun 30, 2022 | 56.86% |
| Mar 31, 2022 | 58.04% |
| Dec 31, 2021 | 66.23% |
| Sep 30, 2021 | 58.25% |
| Jun 30, 2021 | 49.42% |
| Dec 31, 2018 | 46.88% |
| Dec 31, 2017 | -209.58% |
| Dec 31, 2016 | -571.64% |